COVID-19 Information

Find information here

At Novartis, we are committed to patient health and well-being and are closely monitoring the coronavirus disease 2019 (COVID-19) situation. It's important that you take precautions to reduce the risk of contracting COVID-19. Contact your prescribing health care provider if you have any questions or concerns about your treatment with nonimmunosuppressive PROMACTA® (eltrombopag) when considering whether you should receive any vaccine.


Novartis LogoThe Novartis COVID-19 Response Fund is providing urgently needed support for health care workers and communities in more than 50 projects around the world. Novartis established a $20 million global fund in mid-March 2020 to support communities around the world impacted by the COVID-19 pandemic. The fund aims to support public health initiatives designed to help communities manage the challenges posed by the pandemic, such as programs to strengthen health care infrastructure, digital platforms for data collection or dissemination of important public health information, and community health programs.


To learn more about how Novartis is responding to COVID-19, visit


Our Customer Interaction Center can also be reached by phone at: 1‑888‑NOW‑NOVA (1‑888‑669‑6682) Monday to Friday, 8:30 AM - 5:00 PM ET.